The findings open the door to potential large-scale research on generics of MS.
A study at the University of Calgary found promising results for generic drugs Hydroxychloroquine It is the most difficult form of autoimmune disease when used to treat the development of a disorder of primary progressive multiple sclerosis (MS). MS affects approximately 90,000 Canadians, of whom approximately 15% have been diagnosed with primary progressive MS, which is one of the highest rates in the world.
A research team at Cumming School of Medicine, led by Dr. Marcus Kok (MD, PhD) and Dr. Wee Young (PhD), said hydroxychloroquine exacerbated the disorder in an 18-month study involving participants from the MS Clinic in Calgary. I found it useful to delay.The study was published in Annual report of neurology..
“In primary progressive MS, there is no suitable treatment to stop or reverse the progression of the disease. The disorder gradually worsens over time,” said a clinician researcher in the Department of Clinical Neuroscience. And Koch, a member of the Hotchkiss Brian Institute (HBI), said. “Dr. Yong’s research team, with which we work closely, has been screening a large number of generic drugs over the years, and the results with hydroxychloroquine show some promise. Our trial is preliminary. It is a successful and further research is needed. We hope that sharing these results will help inspire the results, especially future large clinical trials. “
An experimental study known as the single-arm phase II futile trial followed 35 individuals between November 2016 and June 2021. At the end of the exam, only eight participants got worse. Hydroxychloroquine was generally well tolerated.
Hydroxychloroquine is a more commonly used antimalarial drug to control the symptoms of autoimmune diseases such as rheumatoid arthritis and lupus. It is widely used in rheumatic diseases and was generally chosen because of its high tolerability.
“Based on our laboratory studies of MS models, we predicted that hydroxychloroquine would reduce the disability of people living with MS. Calgary has a vibrant bench-to-bedside MS program. The results of Dr. Koch’s trial provide further evidence that we were happy to see, “said Yong, a professor of clinical neuroscience and an HBI member.
The cause of MS remains unknown. It is a long-lasting disease in which the body’s immune system attacks its own tissues, often affecting the brain, spinal cord, and optic nerve of the eye. It can cause problems with eyesight, balance, and muscle control, but the effect depends on the person suffering from the disease.
The activities of the MS Clinical Trials team are partially supported by charitable donations from donors such as the Westman Charitable Foundation and the Swartout family. This particular study was also funded by a grant from the MS Translational Clinical Trial Program at the Hotchkiss Brain Institute.
Dr. Koch and his team have been studying the effects of hydroxychloroquine on primary progressive MS for several years, and the study has the potential to achieve even greater results as a treatment in combination with other generic drugs of choice. Including, it continues.
See also: Marcus W. Koch MD, PhD, Sharangit Cowl MPH, Keilasage BHSc, Janet Kim MPH, Miriam Levescroy MD, Dr. Graziera Serchiaro, Dr. Voonweeyon, Gary R. Cutter’s “Primary Progressive Multiple Sclerosis” Hydroxychloroquine PhD and Luanne M. Metz MD, September 30, 2021 Annual report of neurology..
DOI: 10.1002 / ana.26239
Generic drug hydroxychloroquine delays the disorder of the most difficult forms of multiple sclerosis
https://scitechdaily.com/generic-drug-hydroxychloroquine-delays-disability-for-least-treatable-form-of-multiple-sclerosis/ Generic drug hydroxychloroquine delays the disorder of the most difficult forms of multiple sclerosis